SELLAS Life Sciences Group, Inc. Increase (Decrease) in Deferred Revenue
SELLAS Life Sciences Group, Inc. (SLS) reported Increase (Decrease) in Deferred Revenue of $816.00 thousand for the 108-month period ending 2011-12-31, per its 10-K filed 2012-03-28.
Discontinued › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInDeferredRevenue · last filed 2012-03-28
- SELLAS Life Sciences Group, Inc. increase (decrease) in deferred revenue for the quarter ending 2011-12-31 was -$61.00K.
- SELLAS Life Sciences Group, Inc. increase (decrease) in deferred revenue for the quarter ending 2011-09-30 was $299.00K.
- SELLAS Life Sciences Group, Inc. increase (decrease) in deferred revenue for fiscal 2011 was $816.00K.
| Period end | Increase (Decrease) in Deferred Revenue 3 month | Increase (Decrease) in Deferred Revenue 6 month | Increase (Decrease) in Deferred Revenue 9 month | Increase (Decrease) in Deferred Revenue 12 month | Increase (Decrease) in Deferred Revenue 102 month | Increase (Decrease) in Deferred Revenue 105 month | Increase (Decrease) in Deferred Revenue 108 month |
|---|---|---|---|---|---|---|---|
| 2011-12-31 | -$61.00K derived: 10-K 12 month − 10-Q 9 month · filed 2012-03-28 | $238.00K derived: sum of 2 quarters · filed 2012-03-28 | $816.00K 10-K · filed 2012-03-28 | $816.00K 10-K · filed 2012-03-28 | |||
| 2011-09-30 | $299.00K derived: 10-Q 9 month − 10-Q/A 6 month · filed 2011-11-14 | $877.00K 10-Q · filed 2011-11-14 | $877.00K 10-Q · filed 2011-11-14 | ||||
| 2011-06-30 | $578.00K 10-Q/A · filed 2011-10-28 | $578.00K 10-Q/A · filed 2011-10-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 |